QCM Cayman’s Esperion Therapeutics ESPR Stock Holding History

QCM Cayman’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,289	Closed	-$238K	–	116
2018 Q1	$238K	Buy	+3,289	New	+$242K	0.62%	64

Other funds holding ESPR

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

QCM Cayman's ESPR Position: Q2 2018 in Review

QCM Cayman sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 3,289 shares — an estimated $238K sold.

QCM Cayman first reported a position in ESPR in Q1 2018 and held it in 1 quarter. The position peaked at $238K in Q1 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

QCM Cayman reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
QCM Cayman sold 3,289 Esperion Therapeutics shares in Q2 2018, an estimated $238K.
QCM Cayman first reported a position in Esperion Therapeutics in Q1 2018 and held it in 1 quarter.
QCM Cayman's Esperion Therapeutics position peaked at $238K in Q1 2018.
156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on QCM Cayman's 13F filing for Q2 2018, filed 14 Aug 2018.